PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
At present, there are more and more patients with acute hypertriglyceridemia pancreatitis in clinical practice. Common treatment measures include fasting and water withdrawal, fluid resuscitation, and somatostatin. In recent years, studies have pointed out that the PPARa agonist fenofibrate may help...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2021/6629455 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558357825716224 |
|---|---|
| author | Wen Bao Rui Kong Nan Wang Wei Han Jie Lu |
| author_facet | Wen Bao Rui Kong Nan Wang Wei Han Jie Lu |
| author_sort | Wen Bao |
| collection | DOAJ |
| description | At present, there are more and more patients with acute hypertriglyceridemia pancreatitis in clinical practice. Common treatment measures include fasting and water withdrawal, fluid resuscitation, and somatostatin. In recent years, studies have pointed out that the PPARa agonist fenofibrate may help improve the condition of such patients. Therefore, through clinical research and analysis, we reported for the first time that fenofibrate combined with octreotide acetate has a more excellent effect in the treatment of patients with acute hypertriglyceridemia pancreatitis, and from the perspective of signal pathways, we revealed that the combination of the two drugs has an effect on NF-κB P65. The synergistic inhibitory effect proves that the combined treatment is beneficial to control inflammation, protect liver function, and improve the prognosis of patients. It is worthy of clinical promotion. |
| format | Article |
| id | doaj-art-0048044eabb0402db355d04c1a085414 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-0048044eabb0402db355d04c1a0854142025-02-03T01:32:26ZengWileyPPAR Research1687-47571687-47652021-01-01202110.1155/2021/66294556629455PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia PancreatitisWen Bao0Rui Kong1Nan Wang2Wei Han3Jie Lu4Department of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaDepartment of Gastroenterology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, ChinaAt present, there are more and more patients with acute hypertriglyceridemia pancreatitis in clinical practice. Common treatment measures include fasting and water withdrawal, fluid resuscitation, and somatostatin. In recent years, studies have pointed out that the PPARa agonist fenofibrate may help improve the condition of such patients. Therefore, through clinical research and analysis, we reported for the first time that fenofibrate combined with octreotide acetate has a more excellent effect in the treatment of patients with acute hypertriglyceridemia pancreatitis, and from the perspective of signal pathways, we revealed that the combination of the two drugs has an effect on NF-κB P65. The synergistic inhibitory effect proves that the combined treatment is beneficial to control inflammation, protect liver function, and improve the prognosis of patients. It is worthy of clinical promotion.http://dx.doi.org/10.1155/2021/6629455 |
| spellingShingle | Wen Bao Rui Kong Nan Wang Wei Han Jie Lu PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis PPAR Research |
| title | PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis |
| title_full | PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis |
| title_fullStr | PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis |
| title_full_unstemmed | PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis |
| title_short | PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis |
| title_sort | ppar alpha agonist fenofibrate combined with octreotide acetate in the treatment of acute hyperlipidemia pancreatitis |
| url | http://dx.doi.org/10.1155/2021/6629455 |
| work_keys_str_mv | AT wenbao pparalphaagonistfenofibratecombinedwithoctreotideacetateinthetreatmentofacutehyperlipidemiapancreatitis AT ruikong pparalphaagonistfenofibratecombinedwithoctreotideacetateinthetreatmentofacutehyperlipidemiapancreatitis AT nanwang pparalphaagonistfenofibratecombinedwithoctreotideacetateinthetreatmentofacutehyperlipidemiapancreatitis AT weihan pparalphaagonistfenofibratecombinedwithoctreotideacetateinthetreatmentofacutehyperlipidemiapancreatitis AT jielu pparalphaagonistfenofibratecombinedwithoctreotideacetateinthetreatmentofacutehyperlipidemiapancreatitis |